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A B S T R A C T
Objective: To compare the cost-effectiveness of four, six, and eight doses per month of
vardenafil in the context of pharmacy benefit decision making.
Methods: A Markov model was used to estimate the incremental cost-effectiveness of zero,
four, six, or eight doses of vardenafil per month in hypothetical cohorts of 60-year-old male
veterans with erectile dysfunction. Efficacy values for vardenafil were obtained from the liter-
ature, and vardenafil costs were obtained from Veterans Affairs pharmacy data. The analysis
was conducted from a third-party payer perspective with a lifetime horizon, and the effect of
parameter uncertainty was explored in one-way and probabilistic sensitivity analyses.
Results: In the base case analysis, the cost per quality-adjusted life-year gained for four
doses of vardenafil per month compared with no therapy was $576. Six doses per month
comparedwith four cost $2585/quality-adjusted life-year gained, and eight doses permonth
comparedwith six cost $5169/quality-adjusted life-year gained. In one-way sensitivity anal-
yses of six doses per month compared with four, variation of two parameters caused the
incremental cost-effectiveness ratio to cross a willingness-to-pay threshold of $20,000:
when the increased utility associatedwith giving two additional doses/monthwas less than
0.001 (baseline 0.01) and when the cost per dose increased to $15.00 (baseline $1.69).
Conclusion: Although four doses permonth of vardenafil was themost cost-effective strat-
egy, the use of six or eight doses per month also compares favorably with other accepted
medical treatments. The results were stable across a range of inputs and help to support the
current Veterans Affairs policy on the number of vardenafil doses provided per month for
erectile dysfunction.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Published by Elsevier Inc.
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98 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 7 – 1 0 1ntroduction
ardenafil is the oral phosphodiesterase type 5 (PDE5) inhibitor
vailable on the Veterans Affairs (VA) national formulary for the
reatment of erectile dysfunction (ED). VA provides four doses
er month of vardenafil for ED, but greater quantities may be
pproved at the level of the individualmedical center on a case-
y-case basis. Although this policywas based onanaverage inter-
ourse frequency of once per week [1,2], the cost-effectiveness of
roviding additionalmonthly doses of vardenafil is unknown.
The cost-effectiveness of PDE5 inhibitors for ED is well ac-
epted [3,4]. To our knowledge, however, no one has evaluated
he cost-effectiveness of supplying various quantities per
onth. The authors of a cost-utility analysis of sildenafil com-
ared with papaverine-phentolamine injections for ED stated
hat doubling the use of sildenafil almost doubled the cost per
uality-adjusted life-year (QALY) gained [4]. The details of this
nalysis were limited, however, and costs were expressed in
999 British pounds. The objective of this studywas therefore to
ompare the incremental cost-effectiveness of four, six, and
ight doses permonth of vardenafil in a cohort ofmale veterans
ith ED.
ethods
e used a Markov model to estimate the incremental cost-
ffectiveness of zero, four, six, or eight doses of vardenafil per
Table 1 – Parameter values and ranges examined in sensit
Description Base ca
Age of cohort 60
Discount rate 0.03
Probabilities
Potency with vardenafil 0.69
Staying potent 1
Utilities
60-y-old men 0.87
ED disutility 0.13
Increased utility of 6 doses/mo vs. 4 0.01
Reduction in added utility of 8 doses/mo vs. 6 50%
Cost of vardenafil/dose $1.69
Number of 30-d prescriptions/patient/y
Response to vardenafil 11
Vardenafil 
successful 
(potent) Va
uns
(no
Fig. 1 – MNo response to vardenafil 2onth in hypothetical cohorts of 60-year-old male veterans
ith erectile dysfunction. Analyses were conducted from a
hird-party payer perspective (i.e., VA).We used a 3% discount
ate for all costs and benefits, according to the recommenda-
ions of the US Panel on Cost-Effectiveness in Health andMed-
cine [5]. Effectiveness was reported as QALYs to account for
mprovement in quality of life as a result of vardenafil. QALYs
re the product of the time spent in a health state and the
uality of life utility associated with that state summed over
ime. Utilities are a measure of preference for a health state
nd range from 0, representing death, to 1, representing
erfect health. Vardenafil costs were from VA pharmacy
ata through March of fiscal year 2009 and are reported in
S dollars. The cost per dose of vardenafil was based on the
ost per 30-day equivalent prescription for all strengths of
ardenafil (i.e., cost per 30-day prescription divided by 4).
lthough a vast majority of these vardenafil prescriptions
ere for 20-mg strength tablets, the cost per unit for all
trengths was essentially the same. The cost per 30-day
quivalent prescription was used because it reflects the rou-
ine use of tablet splitting for certain strengths of vardenafil.
or example, two 20-mg tablets are dispensed for four
0-mg doses. If the 10-mg dose is not effective, the provider
ill increase the dose to 20 mg. Because vardenafil is not
vailable as a 40-mg tablet, no tablet splitting would occur
or the 20-mg dose.
The Markov model had four health states (Fig. 1). Men
egan in a potent state if vardenafil was successful or an ED
analyses.
Range
Low High Reference
40 80 Assumed (see text)
0.57 0.81 7, 12
0.85 1 9, 10, 11
0.4 1 6
0 0.3 3, 4
0 0.01 Estimate
0% 100% Estimate
$0 $20 VA pharmacy costs
9 12 Estimate
fil 
sful 
nt)
Not on vardenafil 
(not potent) 
v model.b
ivity
serdena
ucces
t pote
Dead 1 3 Estimate
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99V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 7 – 1 0 1tate if vardenafil was unsuccessful. We assumed that var-
enafil was discontinued after two 1-month prescriptions
ere filled if it was not effective (i.e., transition from var-
enafil unsuccessful to not on vardenafil health state,
hich was also an ED state). Men could also die of natural
auses. Although we assumed that men continued to re-
pond to vardenafil in the base case analysis, we did allow
or subsequent failures in the sensitivity analysis (i.e., tran-
ition from vardenafil successful to not on vardenafil). The
odel had a yearly cycle length and a lifetime time horizon
ecause ED is a chronic condition.
Efficacy values for vardenafil were obtained from the
ublished literature (Table 1), except for the increased util-
ty of six and eight doses per month of vardenafil. We were
ery conservative with these estimates and assumed that
ost of the benefit from vardenafil occurs when going from
state of ED to that of being potent. Consistent with this
ssumption, four versus zero doses of vardenafil per month
ere associated with the utilities of potency (i.e., 0.87 in
0-year-old men) [6] and no potency (i.e., utility of potency
inus disutility of ED) [3,4], respectively. We assumed that
he increased utility associated with 6 doses of vardenafil
er month versus 4 was 0.01, and we used a 50% reduction in
he incremental utility gain of 8 doses permonth versus 6 (i.e.,
tility of 0.005). These assumptions bias the analyses against
roviding additional monthly doses. On the basis of available
ata, we assumed that there was no increased morbidity and
ortality related to vardenafil use [7,8] and no loss of treat-
ent effect with time [9–11]. Finally, most vardenafil prescrip-
ions in theVAwere formenbetween theagesof 55and64years,
owe assumed themeanage of the cohort to be 60 years.Wedid
ot specify risk factors for ED (e.g., diabetes, atherosclerosis, rad-
cal prostatectomy, spinal cord injury), because studies have
ound no obvious change in the effectiveness of PDE5 inhibitors
ccording to the cause of ED [7].
ensitivity analyses
he effect of parameter uncertainty was explored in sensitiv-
ty analyses. All the parameters in Table 1 were varied indi-
idually in one-way sensitivity analyses and simultaneously
n probabilistic sensitivity analyses over the ranges specified.
he distributions for the parameterswere chosen according to
he parameter type and level of uncertainty regarding the dis-
ribution. Utility weights were conservatively assigned uni-
orm distributions because they were the most uncertain pa-
ameters, and triangular distributions were used for the cost
Table 2 – Cost-effectiveness of providing various monthly
Strategy (doses/month) Cost Incremen
cost
0 $0.00 —
4 $707.70 $707.70
6 $1061.60 $353.90
8 $1415.50 $353.90f vardenafil and the number of prescriptions filled per patient ver year. Finally, normal distributions were used for age and
he probability of potency with vardenafil [12].
esults
able 2 shows the results of the incremental cost-effective-
ess analysis for zero, four, six, and eight monthly doses of
ardenafil under the base case assumptions. Compared with
roviding no vardenafil, four doses permonth cost $576/QALY
ained. Providing six doses per month versus the current pol-
cy of 4 permonth cost about $2600/QALY gained, and the cost
er QALY gained doubled to approximately $5200 when eight
oses per month were compared with six.
In a one-way sensitivity analysis of the strategy of provid-
ng six doses of vardenafil per month versus four, the results
ere sensitive to the added utility of providing two more
oses permonth and the cost of vardenafil. If the added utility
f two additional doses decreased to 0.001 from 0.01 in the
ase case, then the incremental cost-effectiveness ratio (ICER)
ncreased to $23,261/QALY gained (Fig. 2). If the cost per dose
f vardenafil increased to $15 (base case $1.69), then the ICER
ose to $22,906 (Fig. 3). Further increasing the cost to $17.32,
he average wholesale price of a vardenafil 20-mg tablet in
009, resulted in an ICER of $26,449/QALY gained for the six-
ose strategy. When the cost per dose was $20, the ICERs for
roviding six or eight doses were about $30,500/QALY gained
r $61,000/QALY gained, respectively.
s of vardenafil.
Effectiveness
(QALYs)
Incremental
effectiveness
(QALYs)
ICER
10.13 — —
11.36 1.23 $576
11.50 0.14 $2585
11.57 0.07 $5169
ig. 2 – One-way sensitivity analysis of increased utility of
wo more doses of vardenafil per month. Rx, number ofdose
talardenafil doses per month.
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100 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 7 – 1 0 1In a probabilistic sensitivity analysis of providing six doses
f vardenafil per month versus four, parameter values were
andomly selected 5000 times from the distributions. At a
illingness-to-pay threshold of $50,000/QALY, the strategy
f providing six doses was favored in approximately 84% of
he iterations. At a willingness-to-pay threshold of $20,000/
ALY, supplying six doses per month was favored in almost
3% of the iterations. Compared with six doses, providing
ight doses was favored in 61% of iterations at a threshold of
50,000/QALY gained and in 35% at a $20,000/QALY gained
hreshold.
onclusions
e evaluated the cost-effectiveness of providing various
onthly doses of vardenafil for veterans with ED. Of the strat-
gies investigated, four doses per month was the most eco-
omical approach, as expected, because the monthly cost of
ardenafil increases as the number of doses provided in-
reases and the utility of additional doses does not increase
roportionally. Nevertheless, the use of six or eight doses per
onth also compares favorably with other accepted medical
trategies [13,14], and the results were stable across a wide
ange of inputs. The increased utility of providing additional
oses of vardenafil had to decrease to 0.001 for the ICER to
ncrease to more than $20,000/QALY gained. Although to our
nowledge no one has assessed whether providing additional
oses of vardenafil or other medications for the treatment of
D is associatedwith increased utility, we believe that this is a
easonable assumption given the ability to increase the fre-
uency of intercourse if desired. In addition, we used a very
onservative estimate and assumed that there was a reduc-
ion in the added utility of providing additional doses beyond
ix per month. The results were also sensitive to the cost per
ose of vardenafil. Therefore the cost/QALY gained may be
ignificantly higher in other health care systems, where
ardenafil costs more and where tablet splitting is not used.
lso, the cost per unit for all strengths of vardenafil was
ssentially the same in the VA. This may not be the case in
ther settings and could affect the results of a cost-effec-
ig. 3 – One-way sensitivity analysis of vardenafil cost per
ose. Rx, number of vardenafil doses per month.iveness analysis. Although there is no strict cost-effective-ess criterion in the United States, less than $20,000/QALY
s generally considered to be a good buy [13,14]. In addition,
t would take a fairly large change in the values of specific
arameters, namely the increased utility of providing addi-
ional doses of vardenafil and the cost of vardenafil, to get
bove this threshold.
Although a strength of our analysis is the robustness of the
esults, there are limitations. First,weused the cost of vardenafil
o the VA, which is likely to be lower than the cost of the
edication in other health care settings. We varied the cost
ver awide range in the sensitivity analyses, however, and the
ost per dose had to increase to $15 before the ICER rose above
20,000/QALY gained. Second, we assumed a value of 0.01 for
he utility of two additional monthly doses of vardenafil. In
his case, there had to be almost no benefit from the additional
oses to change the conclusions of our analysis. Third, we did
ot explicitly model adverse events from vardenafil (e.g.,
ardiovascular events, priapism). Although including them
ould increase total costs in the vardenafil groups, the inci-
ence of all serious events was less than 2% in a recent
ystematic review of PDE5 inhibitors for ED [7]. In addition,
he incidence of these events did not differ from placebo [7].
t is therefore unlikely that their inclusion would have
hanged our results. Finally, we used theoretical cohorts of
0-year-old men with ED, and vardenafil may be used both
n younger men, such as those with spinal cord injuries, and
noldermen.Wevaried the age of the cohort from40 to 80 in the
ensitivity analyses, however, and the resulting ICERs did not
hange much.
Albeit the costs per QALY gained in our analysis of zero,
our, six, and eight doses per month of vardenafil were very
easonable, it is important to consider the total cost to the
ystem. In fiscal year 2009, close to 1 million prescriptions
ere filled for vardenafil, at a cost to the VA of more than $9
illion. A cost-effectiveness analysis provides useful infor-
ation, but it is only one piece of data when deciding what
edications to cover. The VA National Formulary provides
or the treatment of ED, with vardenafil as the preferred
DE5 inhibitor, and the results of our cost-effectiveness
nalysis help to support the current policy of providing four
oses per month, with greater quantities approved locally on a
ase-by-case basis. We conclude that supplying four doses of
ardenafil per month for the treatment of ED is the most cost-
ffective strategy for theVA, but our analysis also provides some
upport for providing additional doses. Importantly, the cost-
ffectiveness of furnishingmore doses is sensitive to the cost of
he drug, but supplying six rather than four vardenafil doses per
onth outside theVAsettingwill likely be economically reason-
ble if the drug costs less than $20 per dose.
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